The study and development of anti-angiogenic therapies depends on reliable and reproducible stimulation models of neovascular response. Charles River Discovery Services has several experimental techniques that allow an effective examination of short-term neovascularization and angiogenic response to bFGF, VEGF or other angiogenic stimuli.
Corneal Micropocket Assay
- Hydron pellet prepared with growth factors chosen for specific study requirements
- Surgical implantation of pellet into a corneal micropocket
- Corneal neovascularization measured using slit-lamp microscope
- Short-term study with rapid turnaround times
 
bFGF100 VEGF
bFGF and VEGF Day 6
In vivo screens using angiogenic-dependent tumor growth.
- Bevacizumab can be used as a positive control.
Metronomic dosing (Browder, 2000; Cancer Research 60:1878)
- Long-term, low-level dosing of cytotoxics or other agents of interest to inhibit growth and development of vascular endothelium while avoiding whole-animal toxicity
- Metronomic dose determination for use in efficacy study
- Studies can last up till 90 days.
For more information about our angiogenesis models, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.
|
|
|
corneal neovascularization, angiogenesis model, angiogenesis assay, angiogenesis research, angiogenesis, angiogenesis models, preclinical angiogenesis, metronomic dosing, metronomic, cytotoxics, vascular endothelium, drug efficacy studies, corneal micropocket assay, corneal micropocket, corneal, neovascularization, neovascular, bFGF, VEGF, angiogenic, Hydron pellet, angiogenic tumor cell lines, in vitro drug screening, in vivo drug screening, anti-angiogenesis therapies, piedmont research center
Angiogenesis Models for Examining Corneal Neovascularization | Charles River Discovery Services
Angiogenesis models by Charles River use metronomic dosing and are reliable stimulation models of neovascular response.